Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673897 | 0.89 | GPR119 (0.47) | GPR119MMP13DPP4 | |
| SCHEMBL6058995 | 0.77 | GPR119 (0.48) | GPR119MMP13DPP4 | |
| SCHEMBL1662404 | 0.76 | NR1H2 (0.51) | NR1H2GPR119TSHRDPP4USP2 | |
| SCHEMBL19510734 | 0.75 | GPR119 (0.44) | NR1H2GPR119MMP13TSHRDPP4 | |
| SCHEMBL12179693 | 0.74 | NR1H2 (0.47) | NR1H2GPR119USP2SMN1; SMN2IDO1 | |
| SCHEMBL16419556 | 0.74 | NR1H2 (0.48) | NR1H2GPR119DPP4USP2SMN1; SMN2 | |
| SCHEMBL19510778 | 0.74 | HPGD (0.47) | GPR119MMP13DPP4USP2SMN1; SMN2 | |
| SCHEMBL344483 | 0.74 | HPGD (0.47) | GPR119MMP13DPP4USP2SMN1; SMN2 | |
| SCHEMBL344484 | 0.74 | HPGD (0.47) | GPR119MMP13DPP4USP2SMN1; SMN2 | |
| SCHEMBL334542 | 0.73 | TSHR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | S1PR1, S1PR5, S1PR2 | NR1H2 51/4885GPR119 31/4885MMP13 4070/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | NR1H2 51/4885GPR119 32/4885MMP13 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.